Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Comparative Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine Combinations as First Line Treatment of Metastatic Breast Cancer

NCT00429871 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT00429871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00429871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Comparative Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine Combinations as First Line Treatment of Metastatic Breast Cancer
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2002
Completion date
November 30, 2007
Enrollment
272 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer